Alvogen Prevails On US Zohydro ER Appeal
Two Patents Protecting Hydrocodone Brand Are Invalid
Two treatment patents protecting Persion’s Zohydro ER hydrocodone extended-release tablets until July 2033 are invalid as obvious, the US Court of Appeals for the Federal Circuit has confirmed in a victory for Alvogen.
